Paul J. Merrigan

Chief Commercial Officer at Orphazyme A/S

Paul J. Merrigan

Paul J. Merrigan

Chief Commercial Officer at Orphazyme A/S

Biography

Mr. Paul J. Merrigan is Chief Commercial Officer at Catalyst Pharmaceuticals, Inc.Mr. Merrigan was previously employed as Vice President-Global Marketing by Aegerion Pharmaceuticals, Inc.

Overview
RelSci Relationships

86

Birthday

1961

Age

60

Relationships
RelSci Relationships are individuals Paul J. Merrigan likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder & CSO at Orphazyme A/S

Relationship likelihood: Strong

Chief Financial Officer at Orphazyme A/S

Relationship likelihood: Strong

Head-Patient Advocacy & Patient Services at Dicerna Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Executive Officer & Director at Dansk Biotek

Relationship likelihood: Strong

Chief Medical Officer at Orphazyme A/S

Relationship likelihood: Strong

Chief Executive Officer at CytRx Corp.

Relationship likelihood: Strong

Chief Business Officer at Orphazyme A/S

Relationship likelihood: Strong

Director at Novozymes A/S

Relationship likelihood: Strong

Co-Founder, Chairman, President & Chief Executive Officer at Catalyst Pharmaceuticals, Inc.

Relationship likelihood: Average

Co-Founder & Board of Directors at Catalyst Pharmaceuticals, Inc.

Relationship likelihood: Average

Paths to Paul J. Merrigan
Potential Connections via
Relationship Science
You
Paul J. Merrigan
Chief Commercial Officer at Orphazyme A/S
Education
Master's Degree in Business Administration Business
Class of 2005
Career History
Chief Commercial Officer
Tenure Unconfirmed

Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.

Chief Commercial Officer
2015 - 2016

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Vice President-Global Marketing
2011 - Prior

Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Paul J. Merrigan. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Paul J. Merrigan's profile does not indicate a business or promotional relationship of any kind between RelSci and Paul J. Merrigan.